Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Price Target at $22.83

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $22.83.

NMRA has been the subject of a number of recent analyst reports. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a report on Friday, October 18th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 price target on shares of Neumora Therapeutics in a report on Wednesday, September 4th. HC Wainwright started coverage on Neumora Therapeutics in a research report on Tuesday, October 1st. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Mizuho assumed coverage on Neumora Therapeutics in a research report on Monday, July 8th. They issued an “outperform” rating and a $20.00 target price for the company.

Insiders Place Their Bets

In related news, CFO Joshua Pinto sold 28,496 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $11.63, for a total value of $331,408.48. Following the transaction, the chief financial officer now owns 210,469 shares of the company’s stock, valued at approximately $2,447,754.47. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CFO Joshua Pinto sold 28,496 shares of Neumora Therapeutics stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $11.63, for a total transaction of $331,408.48. Following the transaction, the chief financial officer now directly owns 210,469 shares in the company, valued at approximately $2,447,754.47. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert A. Lenz sold 30,788 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the sale, the insider now owns 339,205 shares of the company’s stock, valued at approximately $4,006,011.05. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 110,538 shares of company stock valued at $1,390,513. Insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Neumora Therapeutics

Hedge funds have recently modified their holdings of the company. Auour Investments LLC purchased a new position in shares of Neumora Therapeutics during the 1st quarter valued at $1,445,000. Callan Capital LLC bought a new position in shares of Neumora Therapeutics in the first quarter worth about $2,819,000. Nan Fung Group Holdings Ltd purchased a new stake in shares of Neumora Therapeutics during the first quarter worth about $871,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Neumora Therapeutics during the first quarter worth about $10,354,000. Finally, Baker BROS. Advisors LP bought a new stake in Neumora Therapeutics during the 1st quarter valued at approximately $8,715,000. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Price Performance

Shares of NASDAQ:NMRA opened at $12.27 on Friday. The business has a fifty day moving average price of $12.91 and a 200-day moving average price of $11.36. The company has a market capitalization of $1.96 billion and a PE ratio of -4.79. Neumora Therapeutics has a 1-year low of $8.33 and a 1-year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.37). On average, sell-side analysts anticipate that Neumora Therapeutics will post -1.48 earnings per share for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.